{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T11:01:20Z","timestamp":1777028480094,"version":"3.51.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1038\/s41401-025-01731-3","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T11:05:35Z","timestamp":1769511935000},"page":"1326-1337","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Human germline-like monoclonal antibody against 5T4 enables potent ADC and CAR-T therapies for solid tumors"],"prefix":"10.1038","volume":"47","author":[{"given":"Yi-qing","family":"Jiang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-jie","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yin-man","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ai-ling","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zi-xuan","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tian-lei","family":"Ying","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-ling","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"key":"1731_CR1","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1038\/leu.2012.18","volume":"26","author":"FV Castro","year":"2012","unstructured":"Castro FV, McGinn OJ, Krishnan S, Marinov G, Li J, Rutkowski AJ, et al. 5T4 oncofetal antigen is expressed in high risk of relapse childhood pre-B acute lymphoblastic leukemia and is associated with a more invasive and chemotactic phenotype. Leukemia. 2012;26:1487\u201398.","journal-title":"Leukemia"},{"key":"1731_CR2","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/bjc.1990.20","volume":"61","author":"PJ Southall","year":"1990","unstructured":"Southall PJ, Boxer GM, Bagshawe KD, Hole N, Bromley M, Stern PL. Immunohistological distribution of 5T4 antigen in normal and malignant tissues. Br J Cancer. 1990;61:89\u201395.","journal-title":"Br J Cancer"},{"key":"1731_CR3","doi-asserted-by":"publisher","first-page":"4236","DOI":"10.1158\/0008-5472.CAN-10-3919","volume":"71","author":"M Damelin","year":"2011","unstructured":"Damelin M, Geles KG, Follettie MT, Yuan P, Baxter M, Golas J, et al. Delineation of a cellular hierarchy in lung cancer reveals an oncofetal antigen expressed on tumor-initiating cells. Cancer Res. 2011;71:4236\u201346.","journal-title":"Cancer Res"},{"key":"1731_CR4","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1097\/00042737-199806000-00008","volume":"10","author":"T Starzynska","year":"1998","unstructured":"Starzynska T, Wiechowska-Kozlowska A, Marlicz K, Bromley M, Roberts SA, Lawniczak M, et al. 5T4 oncofetal antigen in gastric carcinoma and its clinical significance. Eur J Gastroenterol Hepatol. 1998;10:479\u201384.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"1731_CR5","first-page":"1033","volume":"22","author":"H Naganuma","year":"2002","unstructured":"Naganuma H, Kono K, Mori Y, Takayoshi S, Stern PL, Tasaka K, et al. Oncofetal antigen 5T4 expression as a prognostic factor in patients with gastric cancer. Anticancer Res. 2002;22:1033\u20138.","journal-title":"Anticancer Res"},{"key":"1731_CR6","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1046\/j.1525-1438.1995.05040269.x","volume":"5","author":"E Wrigley","year":"1995","unstructured":"Wrigley E, McGown AT, Rennison J, Swindell R, Crowther D, Starzynska T, et al. 5T4 oncofetal antigen expression in ovarian carcinoma. Int J Gynecol Cancer. 1995;5:269\u201374.","journal-title":"Int J Gynecol Cancer"},{"key":"1731_CR7","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1038\/bjc.1992.375","volume":"66","author":"T Starzynska","year":"1992","unstructured":"Starzynska T, Rahi V, Stern PL. The expression of 5T4 antigen in colorectal and gastric carcinoma. Br J Cancer. 1992;66:867\u20139.","journal-title":"Br J Cancer"},{"key":"1731_CR8","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/bjc.1994.173","volume":"69","author":"T Starzynska","year":"1994","unstructured":"Starzynska T, Marsh PJ, Schofield PF, Roberts SA, Myers KA, Stern PL. Prognostic significance of 5T4 oncofetal antigen expression in colorectal carcinoma. Br J Cancer. 1994;69:899\u2013902.","journal-title":"Br J Cancer"},{"key":"1731_CR9","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1158\/1535-7163.MCT-12-0603","volume":"12","author":"P Sapra","year":"2013","unstructured":"Sapra P, Damelin M, Dijoseph J, Marquette K, Geles KG, Golas J, et al. Long-term tumor regression induced by an antibody-drug conjugate that targets 5T4, an oncofetal antigen expressed on tumor-initiating cells. Mol Cancer Ther. 2013;12:38\u201347.","journal-title":"Mol Cancer Ther"},{"key":"1731_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-04756-9","volume":"7","author":"XY Guo","year":"2017","unstructured":"Guo XY, Zheng H, Luo WR, Zhang QB, Liu JX, Yao KT. 5T4-specific chimeric antigen receptor modification promotes the immune efficacy of cytokine-induced killer cells against nasopharyngeal carcinoma stem cell-like cells. Sci Rep. 2017;7:4859.","journal-title":"Sci Rep"},{"key":"1731_CR11","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1002\/mco2.34","volume":"1","author":"CY Guo","year":"2020","unstructured":"Guo CY, Dong E, Lai QH, Zhou SJ, Zhang GB, Wu MD, et al. Effective antitumor activity of 5T4-specific CAR-T cells against ovarian cancer cells in vitro and xenotransplanted tumors in vivo. MedComm (2020). 2020;1:338\u201350.","journal-title":"MedComm (2020)"},{"key":"1731_CR12","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1158\/1078-0432.CCR-16-1834","volume":"23","author":"SA Kerk","year":"2017","unstructured":"Kerk SA, Finkel KA, Pearson AT, Warner KA, Zhang Z, N\u00f6r F, et al. 5T4-targeted therapy ablates cancer stem cells and prevents recurrence of head and neck squamous cell carcinoma. Clin Cancer Res. 2017;23:2516\u201327.","journal-title":"Clin Cancer Res"},{"key":"1731_CR13","first-page":"610","volume":"8","author":"RX Wang","year":"2018","unstructured":"Wang RX, Lai QH, Tang LZ, Tao YR, Yao YQ, Liu Y, et al. A novel 5T4-targeting antibody-drug conjugate H6-DM4 exhibits potent therapeutic efficacy in gastrointestinal tumor xenograft models. Am J Cancer Res. 2018;8:610\u201323.","journal-title":"Am J Cancer Res"},{"key":"1731_CR14","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s00262-016-1917-3","volume":"66","author":"PL Stern","year":"2017","unstructured":"Stern PL, Harrop R. 5T4 oncofoetal antigen: an attractive target for immune intervention in cancer. Cancer Immunol Immunother. 2017;66:415\u201326.","journal-title":"Cancer Immunol Immunother"},{"key":"1731_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2021.107917","volume":"229","author":"YM Jin","year":"2022","unstructured":"Jin YM, Schladetsch MA, Huang XT, Balunas MJ, Wiemer AJ. Stepping forward in antibody-drug conjugate development. Pharmacol Ther. 2022;229:107917.","journal-title":"Pharmacol Ther"},{"key":"1731_CR16","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol. 2023;20:359\u201371.","journal-title":"Nat Rev Clin Oncol"},{"key":"1731_CR17","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.ebiom.2019.10.043","volume":"49","author":"BS Shi","year":"2019","unstructured":"Shi BS, Wu YL, Wang CY, Li XF, Yu F, Wang B, et al. Evaluation of antiviral - passive - active immunization (\u201csandwich\u201d) therapeutic strategy for functional cure of chronic hepatitis B in mice. EBioMedicine. 2019;49:247\u201357.","journal-title":"EBioMedicine"},{"key":"1731_CR18","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3389\/fmicb.2012.00277","volume":"3","author":"P Prabakaran","year":"2012","unstructured":"Prabakaran P, Zhu ZY, Chen WZ, Gong R, Feng Y, Streaker E, et al. Origin, diversity, and maturation of human antiviral antibodies analyzed by high-throughput sequencing. Front Microbiol. 2012;3:277.","journal-title":"Front Microbiol"},{"key":"1731_CR19","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1021\/bc5000109","volume":"25","author":"MT Kim","year":"2014","unstructured":"Kim MT, Chen Y, Marhoul J, Jacobson F. Statistical modeling of the drug load distribution on trastuzumab emtansine (Kadcyla), a lysine-linked antibody drug conjugate. Bioconjug Chem. 2014;25:1223\u201332.","journal-title":"Bioconjug Chem"},{"key":"1731_CR20","doi-asserted-by":"publisher","first-page":"4392","DOI":"10.1021\/jm060319f","volume":"49","author":"WC Widdison","year":"2006","unstructured":"Widdison WC, Wilhelm SD, Cavanagh EE, Whiteman KR, Leece BA, Kovtun Y, et al. Semisynthetic maytansine analogues for the targeted treatment of cancer. J Med Chem. 2006;49:4392\u2013408.","journal-title":"J Med Chem"},{"key":"1731_CR21","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1158\/1535-7163.MCT-22-0804","volume":"22","author":"TD Nguyen","year":"2023","unstructured":"Nguyen TD, Bordeau BM, Balthasar JP. Use of payload binding selectivity enhancers to improve therapeutic index of maytansinoid-antibody-drug conjugates. Mol Cancer Ther. 2023;22:1332\u201342.","journal-title":"Mol Cancer Ther"},{"key":"1731_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/emi.2017.79","volume":"6","author":"YL Wu","year":"2017","unstructured":"Wu YL, Li S, Du LY, Wang CY, Zou P, Hong BB, et al. Neutralization of Zika virus by germline-like human monoclonal antibodies targeting cryptic epitopes on envelope domain III. Emerg Microbes Infect. 2017;6:e89.","journal-title":"Emerg Microbes Infect"},{"key":"1731_CR23","doi-asserted-by":"publisher","first-page":"e1007836","DOI":"10.1371\/journal.ppat.1007836","volume":"15","author":"D Hu","year":"2019","unstructured":"Hu D, Zhu ZY, Li S, Deng YQ, Wu YL, Zhang NN, et al. A broadly neutralizing germline-like human monoclonal antibody against dengue virus envelope domain III. PLoS Pathog. 2019;15:e1007836.","journal-title":"PLoS Pathog"},{"key":"1731_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms9223","volume":"6","author":"TL Ying","year":"2015","unstructured":"Ying TL, Prabakaran P, Du LY, Shi W, Feng Y, Wang YP, et al. Junctional and allele-specific residues are critical for MERS-CoV neutralization by an exceptionally potent germline-like antibody. Nat Commun. 2015;6:8223.","journal-title":"Nat Commun"},{"key":"1731_CR25","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.chom.2017.08.011","volume":"22","author":"F Yu","year":"2017","unstructured":"Yu F, Song H, Wu YL, Chang SY, Wang LL, Li W, et al. A potent germline-like human monoclonal antibody targets a pH-sensitive epitope on H7N9 influenza hemagglutinin. Cell Host Microbe. 2017;22:471\u201383.e5.","journal-title":"Cell Host Microbe"},{"key":"1731_CR26","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","volume":"22","author":"C Dumontet","year":"2023","unstructured":"Dumontet C, Reichert JM, Senter PD, Lambert JM, Beck A. Antibody-drug conjugates come of age in oncology. Nat Rev Drug Discov. 2023;22:641\u201361.","journal-title":"Nat Rev Drug Discov"},{"key":"1731_CR27","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1158\/1535-7163.MCT-14-1095","volume":"14","author":"O Ab","year":"2015","unstructured":"Ab O, Whiteman KR, Bartle LM, Sun X, Singh R, Tavares D, et al. IMGN853, a folate receptor-\u03b1 (FR\u03b1)-targeting antibody-drug conjugate, exhibits potent targeted antitumor activity against FR\u03b1-expressing tumors. Mol Cancer Ther. 2015;14:1605\u201313.","journal-title":"Mol Cancer Ther"},{"key":"1731_CR28","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1056\/NEJMoa2210859","volume":"388","author":"F Del Bufalo","year":"2023","unstructured":"Del Bufalo F, De Angelis B, Caruana I, Del Baldo G, De Ioris MA, Serra A, et al. GD2-CART01 for relapsed or refractory high-risk neuroblastoma. N Engl J Med. 2023;388:1284\u201395.","journal-title":"N Engl J Med"},{"key":"1731_CR29","doi-asserted-by":"publisher","first-page":"e282","DOI":"10.1016\/S2352-3026(24)00377-6","volume":"12","author":"H Jain","year":"2025","unstructured":"Jain H, Karulkar A, Kalra D, Ravikumar S, Shah S, Firfiray A, et al. Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: results from an open-label, multicentre, phase 1\/2 study. Lancet Haematol. 2025;12:e282\u2013e93.","journal-title":"Lancet Haematol"},{"key":"1731_CR30","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1038\/s41591-024-03449-x","volume":"31","author":"C Quintarelli","year":"2025","unstructured":"Quintarelli C, Del Bufalo F, De Ioris MA, Guercio M, Algeri M, Pagliara D, et al. Donor-derived GD2-specific CAR T cells in relapsed or refractory neuroblastoma. Nat Med. 2025;31:849\u201360.","journal-title":"Nat Med"},{"key":"1731_CR31","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1038\/s41401-025-01572-0","volume":"46","author":"YL Yue","year":"2025","unstructured":"Yue YL, Liu JJ, Ma H, Pan ZD, Wang L, Zhang JW, et al. Generating potent and persistent antitumor immunity via affinity-tuned CAR-T cells targeting mesothelin. Acta Pharmacol Sin. 2025;46:2849\u201362.","journal-title":"Acta Pharmacol Sin"},{"key":"1731_CR32","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1186\/s13046-022-02474-3","volume":"41","author":"M Passariello","year":"2022","unstructured":"Passariello M, Yoshioka A, Takahashi K, Hashimoto SI, Inoue T, Nakamura K, et al. Novel tri-specific tribodies induce strong T cell activation and anti-tumor effects in vitro and in vivo. J Exp Clin Cancer Res. 2022;41:269.","journal-title":"J Exp Clin Cancer Res"},{"key":"1731_CR33","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1158\/1535-7163.MCT-16-0825","volume":"16","author":"J Harper","year":"2017","unstructured":"Harper J, Lloyd C, Dimasi N, Toader D, Marwood R, Lewis L, et al. Preclinical evaluation of MEDI0641, a pyrrolobenzodiazepine-conjugated antibody-drug conjugate targeting 5T4. Mol Cancer Ther. 2017;16:1576\u201387.","journal-title":"Mol Cancer Ther"},{"key":"1731_CR34","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1021\/acs.bioconjchem.9b00170","volume":"30","author":"Q Li","year":"2019","unstructured":"Li Q, Barrett A, Vijayakrishnan B, Tiberghien A, Beard R, Rickert KW, et al. Improved inhibition of tumor growth by diabody-drug conjugates via half-life extension. Bioconjug Chem. 2019;30:1232\u201343.","journal-title":"Bioconjug Chem"},{"key":"1731_CR35","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/s41401-023-01200-9","volume":"45","author":"XY Zhu","year":"2024","unstructured":"Zhu XY, Li QX, Kong Y, Huang KK, Wang G, Wang YJ, et al. A novel human single-domain antibody-drug conjugate targeting CEACAM5 exhibits potent in vitro and in vivo antitumor activity. Acta Pharmacol Sin. 2024;45:609\u201318.","journal-title":"Acta Pharmacol Sin"},{"key":"1731_CR36","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","volume":"21","author":"RC Larson","year":"2021","unstructured":"Larson RC, Maus MV. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat Rev Cancer. 2021;21:145\u201361.","journal-title":"Nat Rev Cancer"},{"key":"1731_CR37","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1158\/1535-7163.MCT-24-0052","volume":"24","author":"R Harrop","year":"2025","unstructured":"Harrop R, Blount DG, Khan N, Soyombo M, Moyce L, Drayson MT, et al. Targeting tumor antigen 5T4 using CAR T cells for the treatment of acute myeloid leukemia. Mol Cancer Ther. 2025;24:93\u2013104.","journal-title":"Mol Cancer Ther"},{"key":"1731_CR38","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1097\/CJI.0000000000000203","volume":"41","author":"GL Owens","year":"2018","unstructured":"Owens GL, Sheard VE, Kalaitsidou M, Blount D, Lad Y, Cheadle EJ, et al. Preclinical assessment of CAR T-cell therapy targeting the tumor antigen 5T4 in ovarian cancer. J Immunother. 2018;41:130\u201340.","journal-title":"J Immunother"},{"key":"1731_CR39","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/BF00271369","volume":"44","author":"S Ohlman","year":"1993","unstructured":"Ohlman S, Lindholm A, H\u00e4gglund H, S\u00e4we J, Kahan BD. On the intraindividual variability and chronobiology of cyclosporine pharmacokinetics in renal transplantation. Eur J Clin Pharmacol. 1993;44:265\u20139.","journal-title":"Eur J Clin Pharmacol"},{"key":"1731_CR40","first-page":"89","volume":"4","author":"XY Zhu","year":"2021","unstructured":"Zhu XY, Yu F, Wu YL, Ying TL. Potent germline-like monoclonal antibodies: rapid identification of promising candidates for antibody-based antiviral therapy. Antib Ther. 2021;4:89\u201398.","journal-title":"Antib Ther"},{"key":"1731_CR41","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1093\/jimmun\/vkaf063","volume":"214","author":"GY Zhou","year":"2025","unstructured":"Zhou GY, Zhang YS, Gu YH, Cao BH, Fan X, Yu D, et al. Enhanced antibody-mediated cellular cytotoxicity of germline-like anti-HER2 antibodies through a point mutation in complementarity-determining regions. J Immunol. 2025;214:1849\u201359.","journal-title":"J Immunol"},{"key":"1731_CR42","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1093\/infdis\/jiw080","volume":"213","author":"KV Houser","year":"2016","unstructured":"Houser KV, Gretebeck L, Ying TL, Wang YP, Vogel L, Lamirande EW, et al. Prophylaxis with a middle east respiratory syndrome coronavirus (MERS-CoV)-specific human monoclonal antibody protects rabbits from MERS-CoV infection. J Infect Dis. 2016;213:1557\u201361.","journal-title":"J Infect Dis"},{"key":"1731_CR43","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/s41401-021-00707-3","volume":"43","author":"YJ Jin","year":"2022","unstructured":"Jin YJ, Yu D, Tian XL, Li HX, Zhou XC, Kong Y, et al. A novel and effective approach to generate germline-like monoclonal antibodies by integration of phage and mammalian cell display platforms. Acta Pharmacol Sin. 2022;43:954\u201362.","journal-title":"Acta Pharmacol Sin"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01731-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01731-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01731-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T10:03:16Z","timestamp":1777024996000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01731-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,27]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1731"],"URL":"https:\/\/doi.org\/10.1038\/s41401-025-01731-3","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,27]]},"assertion":[{"value":"31 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}